Physician profile
Brian A Herbst
NPI 1538486576
$3,025.40
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,034 · 2020: $598 · 2021: $848 · 2022: $514 · 2023: $31.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $31.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $31.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $490.31 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $488.33 | 2019-2021 | |
| Lilly USA, LLC | $344.09 | 2019-2023 | Mounjaro |
| Abbvie INC. | $326.09 | 2019-2022 | |
| Amgen INC. | $208.11 | 2020-2022 | |
| Grifols USA, LLC | $196.27 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $188.71 | 2019-2022 | |
| Pfizer INC. | $180.73 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $138.38 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $135.29 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $117.45 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.14 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $54.34 | 2019-2021 | |
| Daiichi Sankyo INC. | $44.88 | 2019-2020 | |
| Abbott Laboratories | $16.01 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $12.85 | 2022 | |
| Neotract INC. | $12.60 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Herbst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.